Home
overview

The latest in our well established series, SMi's 'Asthma & COPD' returns to London in March 2017 to reflect on the ongoing issues and latest developments to these two diseases.

This years' event will bring together industry leaders to discuss the latest challenges and changes in the fields of asthma and COPD. We will explore novel approaches to treatment, exploring biomarkers and targeted treatments. We will identify challenges to device development and rug delivery, deepen our understanding of the problems relating to these diseases, and discuss the hot topic of electronic health monitoring.

Asthma and COPD are two of the most common, and deadly, diseases in the UK. Under diagnosis and incorrect medicine use remain the greatest problems to these diseases. However, cutting edge developments in targeted drugs and personalized treatments are currently revolutionising the ways in which industry are addressing asthma and COPD.

 

 

Presentations and selected case studies from industry experts on asthma and COPD, cutting edge approaches to treatment, key decision makers in these fields and unique networking opportunities will make this an event a not to miss opportunity.

We look forward to seeing you in March.
 

This year's agenda will focus on the challenges experienced by pharmaceuticals as they work to combat asthma and COPD. There will be a strong development focus, and updates on the innovative strategies currently being implemented to overcome long established hurdles to asthma and COPD.

This year will feature two half day workshops, one covering the new and exciting topic of electronic healthcare, a topic set to become a large part of pharmaceutical data collection and healthcare delivery, the other exploring fresh and innovative approaches to COPD. 

Included in this year's speaker panel: 

  • Quan Yang, Pharmaceutical Assessor, MHRA
  • Neil Barnes, Global medical Head, GSK
  • Christopher Stevenson, Venture Leader COPD interception, Janssen,
  • Outi Vaarala, Head of Translational Biology, AstraZeneca
  • Beverley Patterson, Associate Director of Inhalation Clinical R & D, Actavis
  • Stephen Beckman, Head of global respiratory and Allergy, Mylan
  • Stefan Leiner, Chemical-Pharmaceutical Expert, Boehringer Ingelheim
  • Daniela Riccardi, Professor of Physiology, Cardiff University
  • Wisia Wedzicha, Professor of Respiratory Medicine, Imperial College London
  • Marianna Alacqua, Senior Global Medical Affairs Leader of Respiratory Biologics, AstraZeneca
  • David Leather, Global Medical Affairs Leader, GSK
  • Neelima Khairatkar Joshi, Senior Vice President & Head of Drug Discovery, Glenmark Pharmaceuticals

 

 

  • Highlight the latest innovative strategies to tackling asthma and COPD
  • Understand and address the regulatory challenges facing inhalation device development
  • Gain insight into phenotyping and personalized treatments for asthma and COPD 
  • Exclusive case study presentation on the first-of-its-kind 'Salford Lung study' with GSK 
  • Hear from industry leaders on cutting edge developments in biomarker identification and targeted treatments in asthma and COPD 
  • Develop deeper understanding of the ongoing problems still facing asthma and COPD  

Building on last year's event, new topics include: 

  • Regulatory challenges to inhalation device development
  • New approaches to treatment; including cutting edge developments in triple combination therapies and biomarkers
  • Therapeutic developments, including targeted therapies, calcilytics and biologics

Directors, senior scientists, principle scientists, associate directors, managing directors, medical directors, pharmaceutical experts, inhalation toxicologists of the following departments: 

  • clinical pharmacology
  • respiratory medicine
  • respiratory immunology
  • pulmonary specialty
  • respiratory physiology

 

 

3M Health Care; Aerocrine; Aerocrine AB; AstraZeneca; Biomedical Systems BV; Boehringer Ingelheim; Bosch Healthcare Solutions GmbH; Campbelltown Hospital; Chiesi Farmaceutici S. P. A. ; Chiesi Farmaceutici S.p.A.; Dr Reddys Laboratories; ELPEN Pharmaceutical Co. Inc; Fidelta Ltd; Glenmark Pharmaceuticals; GSK; Imperial College London; inVentiv Health. Clinical; IU Health goshen; MedImmune; MEDWAY MARITIME HOSPITAL ; Mylan Pharma UK; Next Breath; Novartis Pharma AG; Orion Pharma AB; Protalix Ltd.; Roche Products Limited; Samedan Ltd; Santisham Chest Hospital; SHL Group AB; Teva UK Ltd; Thomson Reuters; University College London; University of Glasgow; Verona Pharma;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

9:10 EU & UK regulatory consderations for the development of inhaled products

Quan Yang

Quan Yang, Pharmaceutical Assessor, MHRA
View Bio

• EU and UK regulatory hurdles to developing and registering a generic inhalation product 
• Regulations for inhalation drug development, including combination considerations
• Regulatory updates on the device component of a medicinal product
• How does device type affect the development and approval process?

9:50 Overcoming challenges to industry in the device development process

Stefan Leiner

Stefan Leiner, Chemical-Pharmaceutical Expert, Boehringer Ingelheim
View Bio

• Moving away from generic development
• Taking age group into consideration when developing a device; considerations for paediatric and elderly patients
• Incorporating clinical trials as a key step in obtaining device approval
• USP regulatory update on spacers in new devices 

10:30 Morning Coffee

11:00 From molecule to medicine - formulation development and manufacturing of dry powder inhalation products

Frank Thielmann

Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG
View Bio

• Device and formulation systems and their selection
• Drug substance ~ product relationship. How does performance in vitro relate to performance in vivo?
• Challenges in the manufacturing of DPI systems
• Future trends in inhaled drug delivery

12:20 Networking Lunch

13:30 Matching device and treatment to disease stage; considerations for the treatment of asthma

Ewan Walters

Ewan Walters, Medical Director, Teva UK Ltd

 

·          Clinical development of novel inhalers – trends with case study examples
·          Challenges to the development of novel inhalers; increased cost of development vs. improved performance and decreased cost to NHS
·          Targeting severe exacerbation with novel monoclonal antibodies
o    Mechanism for targeting and exacerbation reduction
o    Knock on effects to NHS and pricing strategies

14:10 Inhaled calcilytics for inflammatory lung disease

Daniela  Riccardi

Daniela Riccardi , Deputy Head of Schoo, School of Biosciences , University Of Cardiff
View Bio

• The calcium-sensing receptor as a novel drug target for asthma and COPD
• Calcilytics prevent asthma-associated airways hyper-responsiveness and inflammation
• Calcilytics in eosinophilic and neutrophilic models of inflammatory lung disease
• Targeting a potential root of inflammatory lung disease
 

14:50 Application of biomarkers and patients characteristics to personlaise treatment of Asthma and COPD

Marianna Alacqua

Marianna Alacqua, Sr Global Medical Affairs Leader Respiratory Biologics, AstraZeneca Plc

15:30 Afternoon Tea

16:00 Biologics; targeted treatment to targeted cases

Donna Finch

Donna Finch, Principal Scientist, Respiratory, Inflammation and Autoimmunity, MedImmune

• Case study
• Current patient selection strategies for identifying best treatment
• Moving towards personalised treatments for asthma and COPD

16:40 Identifying eosinosphil biomarkers for targeted therapeutic treatment of COPD

Wisia  Wedzicha

Wisia Wedzicha, Professor of Respiratory Medicine , Imperial College London

• Predicting patient response to inhaled corticosteroids using blood eosinophils
• How blood eosinophils can be used to adjust treatment approach
• Implications for future treatment strategies

17:20 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Stephen Beckman

Stephen Beckman, Head of Global Respiratory, Mylan Pharmaceuticals
View Bio

9:10 Integration of innovation and opportunity in COPD

Stephen Beckman

Stephen Beckman, Head of Global Respiratory, Mylan Pharmaceuticals
View Bio

• Innovation serving new ways to treat and manage unique sub populations in COPD
• Impact of RX and GX solutions in COPD and Asthma
• How advanced delivery solutions will impact the market
• Changes in payer and provider care impacts innovation
• What trends will most affect the next ten years in Asthma and COPD

9:50 Early interception of COPD

Christopher Stevenson

Christopher Stevenson, Venture Leader, COPD Interception, Janssen

• Focussing on early identification of COPD using targeted biomarkers and identifying related disease pathways
• Impact of early interception to later disease course, progression and treatment strategies
• Integrating novel therapeutics and diagnostics to address patient susceptibility to COPD

10:30 Morning Coffee

11:00 Novel anti-inflammatory approaches in the treatment of COPD

Neelima Khairatkar-Joshi

Neelima Khairatkar-Joshi, Vice President and Head, In vitro Biology, Glenmark Research Centre

  • Lung inflammation orchestrations in COPD 
  • Past and present approaches to anti-inflammatory approaches
  • Breaking down inflammation; from animals to man to patients; mind the gap
  • Will novel targets deliver novel therapeutics in COPD 
  • 11:40 Phenotyping asthma and COPD disease types

    Neil Barnes

    Neil Barnes, Head of Respiratory Medicine , GlaxoSmithKline R&D

    • Rethinking diagnosis criteria for asthma and COPD based on genetic phenotyping
    • Impacts of phenotyping on treatment type, and individuality of treatment
    • Patient stratification using phenotypic patient subsets
     

    12:20 Networking Lunch

    13:30 'Real time data collection' - The Salford Lung Study

    David Leather

    David Leather, Global Medical Affairs Leader, GSK
    View Bio

    • A first of its kind study to demonstrate the effectiveness of Relvar Ellipta in COPD and asthma patients
    • Study overview, aims and background
    • Benefits of real time data collection – setting future trends?
    - Comparing the representativeness of effectiveness studies vs randomised double blind controlled studies
    - Drivers of effectiveness; for example adherence, comorbidity and age
    • Implications of integrated health systems
    - Changing patient ~ clinician relationships

    14:10 Recent advances in drug development and treatments for Asthma and COPD

    Beverley Patterson

    Beverley Patterson, Inhalation Clinical Associate Director, Actavis

    • Current treatment options for asthma and COPD
    • Moving forward: Insilico, PK and PD modelling and simulation methods for evaluating respiratory drugs
    • Assessing drug performance and dose response relationships using a PKPD approach
    • Increasing weight of evidence for the evaluation of the safety and efficacy of respiratory drugs

    14:50 Afternoon Tea

    15:30 Identifying novel biomarkers to determine patient response to respiratory drugs

    Outi Vaarala

    Outi Vaarala, VP, Head of Tranlsational Biology, Astrazeneca

    16:40 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Daniela  Riccardi

    Daniela Riccardi

    Deputy Head of Schoo, School of Biosciences , University Of Cardiff
    David Leather

    David Leather

    Global Medical Affairs Leader, GSK
    Frank Thielmann

    Frank Thielmann

    Operational Lead, Inhalation New Solids, Novartis Pharma AG
    Monica  Fletcher

    Monica Fletcher

    Chief Executive Officer, Education for Health
    Outi Vaarala

    Outi Vaarala

    VP, Head of Tranlsational Biology, Astrazeneca
    Quan Yang

    Quan Yang

    Pharmaceutical Assessor, MHRA
    Stefan Leiner

    Stefan Leiner

    Chemical-Pharmaceutical Expert, Boehringer Ingelheim
    Stephen Beckman

    Stephen Beckman

    Head of Global Respiratory, Mylan Pharmaceuticals
    Wisia  Wedzicha

    Wisia Wedzicha

    Professor of Respiratory Medicine , Imperial College London

    Beverley Patterson

    Inhalation Clinical Associate Director, Actavis
    Beverley Patterson

    Christopher Stevenson

    Venture Leader, COPD Interception, Janssen
    Christopher Stevenson

    Daniela Riccardi

    Deputy Head of Schoo, School of Biosciences , University Of Cardiff
    Daniela  Riccardi

    Daniela Riccardi obtained her BA in Zoology and MRes in Physiopathological methods from the University of Milan, Italy, where she investigated mechanisms of water transport in mammalian epithelia. Her PhD in Physiology was completed working between the University of Milan and the Harvard Medical School, Boston, USA, under the supervision of Prof. SC Hebert, in the Renal Division of the Brigham and Women's Hospital. Daniela was part of the team that identified the extracellular calcium-sensing receptor, CaR, which is the first G protein-coupled receptor hah has an ion, calcium, as its ligand. She then went on to identify the renal calcium-sensing receptor. Following her work on the CaR, Daniela was awarded the first prize in Excellence in Research from the American Society of Nephrology and National Kidney Foundation, a Research Fellowship from the National Kidney Foundation and The Wellcome Trust Prize for Excellence in Physiology. In 1997, Daniela moved to the UK and established her own research group at Manchester University, remaining there until 2004. In 2004, she moved to the School of Biosciences at Cardiff University where currently she is Professor of Physiology and Deputy Head of the School of Biosciences. Daniela’s research interests centre on how cells sense and respond to perturbations in the extracellular milieu, particularly Ca2+, polycations and nutrients. Daniela’s scientific goals are: 1. to develop CaSR antagonists (calcilytics) as novel therapeutics for inflammatory lung disease, and; 2. to define the role of the CaSR in blood pressure control and in the prevention of vascular calcification.

    David Leather

    Global Medical Affairs Leader, GSK
    David Leather

    Dave Leather is a Global Medical Affairs Leader in the Respiratory Franchise at GSK, based at GSK House in London in the UK. He leads the Global Medical Expert team: a team of world renowned Respiratory experts who work for GSK providing internal scientific and clinical expertise to support promoted medicines and those in development. For the last 3 years he led a team responsible for developing phase lll and phase lV trials for respiratory medicines. He also has a leadership role in “real world pragmatic trials” and is the Franchise leader of the internationally recognised Salford Lung Study.
    Dave joined GSK in 2000 and has held a variety of posts within the company. Originally a primary care physician in Bolton with an interest in respiratory disease, Dave managed asthma and COPD clinics in a primary care setting and held a post as a clinical assistant in Respiratory Medicine at University Hospital Aintree in Liverpool. He was a GP Course Organiser, a member of the Council of the Royal College of GPs (RCGP), and worked as a media doctor for the BBC and commercial radio.
     

    Donna Finch

    Principal Scientist, Respiratory, Inflammation and Autoimmunity, MedImmune
    Donna Finch

    I am currently Principal Scientist and Team Leader in Respiratory, Inflammation and Autoimmunity (RIA) at MedImmune Ltd, Cambridge, UK, having joined 18 years ago when Cambridge Antibody Technology.
    My team is currently focussed on investigating novel mechanisms and target generation in the pathogenesis of COPD (chronic obstructive pulmonary disease). We focus on human biology, accessing valuable disease lung samples, and using innovative 3D-culture techniques, imaging and –omics technologies. Along with RIA and Translational Science colleagues at our Gaithersburg site, we address patient stratification in COPD, and we are particularly interested in biomarkers and epidemiology of exacerbations of COPD. I have been involved in multiple drug projects in COPD and inflammatory diseases (such as rheumatologic disease), leading several biologic therapies through to early clinical trials (such as antibodies to interleukin 6, interleukin-1RI, and others). I am an Industrial Lead for the UK Consortium COPD-MAP, and we work directly with Spiromics and COPD-GENE investigators (US consortia), and collaborate extensively with key COPD investigators worldwide.
    I have previously worked for Glaxo Group Research (UK), and Roche Biosciences (Palo Alto, Ca, USA), and I achieved my BSc from University of Bristol, and my PhD from University of Leicester, where I studied the signalling and function of muscarinic receptors in smooth muscle.
     

    Ewan Walters

    Medical Director, Teva UK Ltd
    Ewan Walters

    Frank Thielmann

    Operational Lead, Inhalation New Solids, Novartis Pharma AG
    Frank Thielmann

    Dr Thielmann graduated from University of Duesseldorf, Germany in 1996 with a diploma in Chemistry. This was followed by a PhD in Physical Chemistry in 1998 in the area of materials characterisation. Frank then worked for a private materials testing institute in Hannover, Germany before joining Surface Measurement Systems UK (SMS) in 2000. He stayed with SMS for eight years in different roles including global Head of Application Science. In this role, he was heavily involved in the development of novel characterisation methods for the challenges in the modern pharmaceutical industry with focus on inhalation and oral solid dosage forms. Frank joined the Inhalation Development Unit of Novartis Pharma (Basel, Switzerland) in July 2007 as Formulation Lab Head. From August 2009 until February 2011 he managed the inhalation & device development group at the Horsham site, UK. Upon his return to Basel he took on the responsibility for the local inhalation technology platform until February 2012. Subsequently he joined Novartis Pharmaceutical Operations where he is now the Lead for the manufacturing of new inhalation products.
    Dr Thielmann is member of the Steering Committee of the Material Science Focus Group in the British Academy of Pharmaceutical Sciences. He is an author and co-author of more than 25 articles in peer reviewed journals as well as author and co-author of more than 50 oral presentations at international conferences and seminars and over 80 scientific posters.
     

    Marianna Alacqua

    Sr Global Medical Affairs Leader Respiratory Biologics, AstraZeneca Plc
    Marianna Alacqua

    Monica Fletcher

    Chief Executive Officer, Education for Health
    Monica  Fletcher

    Neelima Khairatkar-Joshi

    Vice President and Head, In vitro Biology, Glenmark Research Centre
    Neelima Khairatkar-Joshi

    Dr. Neelima Khairatkar-Joshi is a Sr. Vice President & Head, NCE Drug Discovery Research at Glenmark Pharmaceuticals, New Mumbai, India. She has over 24 years of experience in the New Drug Discovery research.

    In her current role, she is responsible for driving all preclinical decisions leading to identification of an IND enabling lead candidate in therapy areas of Inflammation, Chronic Pain and Respiratory Disease. During her 16 years career at Glenmark, she has successfully contributed to deliver numerous IND enabling innovative molecules that progressed into clinical trials. Dr. Neelima is an inventor on over 80 published patents (world), has authored over 50 abstracts and 10 peer reviewed publications / book chapters of renowned publishers / journals such as Elsevier, Expert Opinion, Trend and Molecular Medicine. She has presented over 15 invited lectures in key international forums in areas of drug discovery.

    Prior to joining Glenmark, Dr Neelima worked on natural product based New Drug Discovery Research at Hoechst Marion Roussel (Now Sanofi Avantis) for about 8 years. She earned her Ph.D. in Molecular Biology, Masters in Microbiology.
     

    Neil Barnes

    Head of Respiratory Medicine , GlaxoSmithKline R&D
    Neil Barnes

    Outi Vaarala

    VP, Head of Tranlsational Biology, Astrazeneca
    Outi Vaarala

    Quan Yang

    Pharmaceutical Assessor, MHRA
    Quan Yang

    Dr Yang is a Pharmaceutical Assessor at the Medicines and Healthcare Products Regulatory Agency (MHRA) in London. She is responsible for assessing the chemical and pharmaceutical data in relation to abridged applications (national, mutual recognition, decentralised and centralised) and new applications of topical products including inhaled products, dermatological products and endocrine systems. Dr Yang has been involved in the assessment of applications for new inhaled products, including dry powder inhalers and MDI’s, and the provision of Scientific Advices for both national and European centralised procedures. Dr Yang is a UK registered pharmacist and holds a PhD in pharmaceutical science.

    Stefan Leiner

    Chemical-Pharmaceutical Expert, Boehringer Ingelheim
    Stefan Leiner

    Dr. Stefan Leiner is a pharmacist by training and joined Boehringer Ingelheim in Germany in 1987. After a couple of years in manufacture, galenical and analytical development, he focussed on inhalation forms.

    He now holds the title of a “CMC Expert", meaning he is responsible for the scientific standard of the Module 3 of MAAs. He wrote the Quality Overall Summaries for many of Boehringer Ingelheim’s new inhalation developments.

    Stefan Leiner represents Boehringer Ingelheim in the International Pharmaceutical Aerosol Consortium - Regulation and Science (IPAC-RS) and was chair of this organization. He participated in the development of the ISO 20072 Standard on "Aerosol Drug Delivery Devices". He is active in the German Pharmacopeia.
     

    Stephen Beckman

    Head of Global Respiratory, Mylan Pharmaceuticals
    Stephen Beckman

    Stephen Beckman has devoted his entire 24-year career to the life sciences industry in a broad range of operational and commercial positions within both regional (US) and global organizations. During his career, Stephen has become an expert in a number of therapeutic areas including respiratory and rare diseases as well as specific subject matter areas in commercial operations, start-up management, strategic planning, business development, product launch, and partnership management. He is currently Head of Global Respiratory and Allergy at Mylan, Inc. In this role he is responsible for the global strategy and implementation of the respiratory and allergy portfolio which is expected to exceed $2 billion by 2018. Previously, Mr Beckman was the President/Director of North America for Pharmaxis, Inc. with responsibility over all business activities for both North and South America. Mr. Beckman lead the efforts for the US approval of Aridol®, a novel new asthma diagnostic and the approval efforts for Bronchitol® for the treatments of cystic fibrosis and bronchiectasis.
    Stephen has demonstrated a consistent ability to effectively work within emerging pharmaceutical companies such as Pharmaxis as General Manager of Exaeris, Inc. as well as successful track records in a number of large pharmaceutical concerns as Corporate Vice President of Global Marketing at Altana Pharmaceuticals and Worldwide Director of Pulmonary at SmithKline Beecham Pharmaceuticals (GSK). It has been through these diverse experiences that Mr. Beckman has been able to develop critical skill sets such as entrepreneurial ingenuity, transparent leadership, strategic communication, and critical thinking required to deliver sustainable solutions within the ever-changing landscape of the Pharmaceutical Industry.
    The pathway to these positions has been built from a career in sales and product management, licensing, and portfolio development with Astra Zeneca, and Fisons Pharmaceuticals.
    Stephen earned his B.S., in business from Syracuse University with an additional concentration in Advertising and Communications. He actively participates in the life sciences community through a number of industry boards, committees and lecturing which include:
    • University of Pennsylvania (Wharton) Executive MBA – annual guest lecturer on business strategy and human capital.
    • Adjunct lecturer at St. Joseph’s University Pharmaceutical Executive MBA.
    • Committee member Genesyn IP Ventures in association with Temple University School of Medicine and health system.
     

    Vaishali Kamat

    Director, Digital Health, Cambridge Consultants Ltd
    Vaishali Kamat

    Wisia Wedzicha

    Professor of Respiratory Medicine , Imperial College London
    Wisia  Wedzicha

    Official Media Partner

    Official Publication

    Supporters

    Workshops

    The future of Asthma & COPD management; from connected inhalers to therapy management
    Workshop

    The future of Asthma & COPD management; from connected inhalers to therapy management

    Holiday Inn Kensington Forum
    28th March 2017
    London, United Kingdom

    Innovative approaches to COPD – Proactive, not reactive strategies
    Workshop

    Innovative approaches to COPD – Proactive, not reactive strategies

    Holiday Inn Kensington Forum
    28th March 2017
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Media Partners


    ONdrugDelivery Magazine

    Official Media Partner
    http://ondrugdelivery.com

    ONdrugDelivery Magazine is the highly regarded, world-leading series of sponsored themed drug delivery publications. Uniquely, each issue focuses tightly on one topic within the field of drug delivery. With a truly global readership already in excess of 40,000, and with contributions and loyal support from many of the most important companies in the drug delivery business - from among the largest to the smallest - ONdrugDelivery Magazine is a must for those in the industry who need to know what's going on in drug delivery.

    Media Partners


    International Journal of Medical Engineering and Informatics

    Official Publication
    http://www.inderscience.com/ijmei

    IJMEI promotes an understanding of the structural/functional aspects of disease mechanisms and the application of technology towards the treatment/management of such diseases. It seeks to promote interdisciplinary collaboration between those interested in the theoretical and clinical aspects of medicine and to foster the application of computers and mathematics to problems arising from medical sciences. IJMEI includes authoritative review papers, the reporting of original research, and evaluation reports of new/existing techniques and devices. Each issue also contains a comprehensive information service.


    Int. J. of Immunological Studies

    Official Publication
    http://www.inderscience.com/ijis

    IJIS publishes a broad range of papers on all aspects of immunology from scientists in academic and non-academic organisations as well as business and government worldwide. IJIS is the flagship journal of the Frontiers in Immunology Research Network.


    International Journal of Biomedical Engineering and Technology

    Official Publication
    http://www.inderscience.com/ijbet

    IJBET addresses cutting-edge research in the multi-disciplinary area of biomedical engineering and technology. Medical science incorporates scientific/technological advances combining to produce more accurate diagnoses, effective treatments with fewer side effects, and improved ability to prevent disease and provide superior-quality healthcare. A key field here is biomedical engineering/technology, offering a synthesis of physical, chemical, mathematical and computational sciences combined with engineering principles to enhance R&D in biology, medicine, behaviour, and health. IJBET includes the Asia-Pacific Chapter in Biomedical Wireless Technology (APC-BWT).


    International Journal of Healthcare Technology and Management

    Official Publication
    http://www.inderscience.com/ijhtm

    IJHTM is a series emerging from the International Journal of Technology Management. It provides an international forum and refereed authoritative sources of information in the fields of the economics and management of technology in healthcare.


    International Journal of Biotechnology

    Official Publication
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


    International Journal of Technology, Policy and Management

    Official Publication
    http://www.inderscience.com/ijtpm

    IJTPM is a refereed international journal that provides a professional and scholarly forum in the emerging field of decision making and problem solving in the integrated area of technology policy and management at the operational, organisational and public policy levels.

    Media Partners


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharmaceutical Manufacturing and Packing Sourcer (PMPS)

    Supporters
    http://www.samedanltd.com/magazine/15

    Pharmaceutical Manufacturing and Packing Sourcer (PMPS) is a specialist magazine for the pharmaceutical manufacturing, packaging and supply chain sectors. Every quarterly edition features articles written by key opinion leaders, ranging from pharmaceutical sponsors and key services providers, to industry associations and regulatory authorities. PMPS combines technological, operational and corporate perspectives on this growing sector, along with industry interviews, event previews and book reviews. Now you can also read PMPS on the go with the new Samedan app. Click here to download it now for your iPhone or iPad: http://bit.ly/IJECug


    BioChem Adda

    Supporters
    https://www.biochemadda.com/

    BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!


    BioPharm Insight

    Supporters
    http://www.infinata.com/biopharma-solution/by-product/biopharm-insight.html

    BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


    Labhoo

    Supporters
    http://www.labhoo.com



    Thieme

    Supporters
    http://www.thieme.com/

    Thieme is an award-winning international medical and science publisher promoting the latest research findings in its books, journals, and electronic products. Seminars in Respiratory and Critical Care Medicine is a topic-driven review journal providing comprehensive coverage of respiratory and pulmonary disorders. The journal includes new diagnostic and therapeutic procedures, genetic breakthroughs and clinical management as related to such areas as lung or pleural diseases, cystic fibrosis and many other related disorders. Link to the journal: https://www.thieme.de/de/seminars-respiratory-critical-care-medicine/journal-information-9821.htm


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Crowd Reviews

    Supporters
    https://www.crowdreviews.com/best-investment-management-software

    CrowdReviews.com is a transparent online platform for determining which products and services are the best based on the opinion of the crowd. The crowd consists of Internet users which have experienced products and services first-hand and have an interest in letting other potential buyers their thoughts on their experience.


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.